Adjunctive Semaglutide Explored for Cognitive Dysfunction in Depression

Major Depressive Disorder (MDD) often presents with significant cognitive dysfunction, including issues with memory, attention, and executive function, which can persist even after mood symptoms improve. These cognitive deficits significantly impair daily functioning and quality of life for patients. Current antidepressant treatments primarily target mood, leaving a substantial unmet need for therapies that specifically address cognitive impairment in MDD. This Phase 2 study was designed to evaluate if adjunctive semaglutide could improve cognitive function in individuals with MDD.

This Phase 2 study, which completed its intervention phase in December 2024, aimed to investigate the potential of semaglutide to improve cognitive function in individuals with Major Depressive Disorder (MDD). While specific results are pending publication, the researchers hypothesized that semaglutide would demonstrate a significant improvement in various cognitive domains compared to placebo. The primary objective was to assess changes in cognitive scores, with secondary outcomes likely including mood symptom changes and tolerability. The 72 participants were carefully monitored for any cognitive improvements, which, if positive, would suggest a novel therapeutic avenue for a challenging aspect of depression. The study's core hypothesis was that adjunctive semaglutide would lead to a measurable and statistically significant enhancement in cognitive performance in MDD patients over 16 weeks compared to placebo.